208 related articles for article (PubMed ID: 29335436)
1. Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.
Chen M; Wan L; Zhang J; Zhang J; Mendez L; Clohessy JG; Berry K; Victor J; Yin Q; Zhu Y; Wei W; Pandolfi PP
Nat Commun; 2018 Jan; 9(1):159. PubMed ID: 29335436
[TBL] [Abstract][Full Text] [Related]
2. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
Wu PK; Hong SK; Park JI
Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
[TBL] [Abstract][Full Text] [Related]
3. Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer.
Chatterjee A; Chatterjee U; Ghosh MK
Cell Death Dis; 2013 Mar; 4(3):e543. PubMed ID: 23492774
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells.
Misra UK; Pizzo SV
Cell Signal; 2004 Apr; 16(4):487-96. PubMed ID: 14709337
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate.
Pandey SK; Théberge JF; Bernier M; Srivastava AK
Biochemistry; 1999 Nov; 38(44):14667-75. PubMed ID: 10545192
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
[TBL] [Abstract][Full Text] [Related]
8. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling.
Shrestha Y; Schafer EJ; Boehm JS; Thomas SR; He F; Du J; Wang S; Barretina J; Weir BA; Zhao JJ; Polyak K; Golub TR; Beroukhim R; Hahn WC
Oncogene; 2012 Jul; 31(29):3397-408. PubMed ID: 22105362
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
10. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling.
Yan G; Ru Y; Yan F; Xiong X; Hu W; Pan T; Sun J; Zhang C; Wang Q; Li X
Cell Commun Signal; 2019 May; 17(1):44. PubMed ID: 31092266
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
13. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
14. A hexane fraction of guava Leaves (Psidium guajava L.) induces anticancer activity by suppressing AKT/mammalian target of rapamycin/ribosomal p70 S6 kinase in human prostate cancer cells.
Ryu NH; Park KR; Kim SM; Yun HM; Nam D; Lee SG; Jang HJ; Ahn KS; Kim SH; Shim BS; Choi SH; Mosaddik A; Cho SK; Ahn KS
J Med Food; 2012 Mar; 15(3):231-41. PubMed ID: 22280146
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling.
Han Y; Fang J; Xiao Z; Deng J; Zhang M; Gu L
J Cancer Res Clin Oncol; 2021 Mar; 147(3):767-777. PubMed ID: 33389075
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway.
Lenormand P; McMahon M; Pouysségur J
J Biol Chem; 1996 Jun; 271(26):15762-8. PubMed ID: 8663120
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses.
Riedl A; Schlederer M; Pudelko K; Stadler M; Walter S; Unterleuthner D; Unger C; Kramer N; Hengstschläger M; Kenner L; Pfeiffer D; Krupitza G; Dolznig H
J Cell Sci; 2017 Jan; 130(1):203-218. PubMed ID: 27663511
[TBL] [Abstract][Full Text] [Related]
20. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
